R. Ziesche et al., Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension, HEART, 83(4), 2000, pp. 406-409
Citations number
17
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objective-To assess whether long term treatment with epoprostenol might res
tore primary non-responsiveness to nitric oxide (NO) in patients with prima
ry pulmonary hypertension.
Methods-Seven patients with primary pulmonary hypertension receiving intrav
enous epoprostenol continuously because of failure of NO to influence pulmo
nary haemodynamics during initial testing were followed over a period of 13
-29 months. Afterwards, acute Vascular reactivity towards NO was rested aga
in during right heart catheterisation.
Results-Administration of NO after continuous epoprostenol treatment for a
mean period of 18 months improved arterial oxygen saturation (p < 0.01) and
cardiac index (p < 0.05), and decreased mean pulmonary artery pressure (p
< 0.01) and total pulmonary vascular resistance (p < 0.01) in patients prev
iously unresponsive to NO.
Conclusions-Long term treatment with epoprostenol reverts initial refractor
iness to NO in patients with primary pulmonary hypertension. Thus the addit
ion of NO to epoprostenol treatment might cause further improvement in the
course of the disease.